Argenx Advances Efgartigimod Into China With Zai Lab Pact
Selects Option Of $75m In Stock For Upfront
Executive Summary
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
You may also be interested in...
Launch Of Vyvgart Exceeds Argenx’s Expectations
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
Argenx, Calliditas Hit The Ground Running After FDA Approvals
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.
Argenx's Ambitious Plans For Efgartigimod On Track
The company's first-in-class FcRn antagonist, which has an FDA action date in December, is now being reviewed by the EMA and although the regulator rejected a request for an accelerated assessment of efgartigimod for generalized myasthenia gravis, commercial teams are being built up in Europe.